CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Files An 8-K Financial Statements and ExhibitsItem 9.01
|
Exhibit No. |
Description |
| 1.1 | Underwriting Agreement, dated July18, 2017 |
| 5.1 | Opinion of Cooley LLP |
| 23.1 | Consent of Cooley LLP (contained in Exhibit 5.1) |
CymaBay Therapeutics, Inc. ExhibitEX-1.1 2 d429581dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 EXECUTION VERSION 13,…To view the full exhibit click here
About CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
